German Echocardiography Congress of the DGK Deutsche Gesellschaft für Kardiologie #EchoDGK23 The 20th Anniversary of the Echocardiography Congresses in #Leipzig When: 🗓️ 01.06.2023-04.06.2023 Where: goo.gl/maps/KZohEsmEz… Programme: bit.ly/3ZjJVYg Registration: bit.ly/3ncz3O5

#EUROPACE_FRESH_OFF_THE_PRESS Does #AF ablation impact dementia risk? Bart Mulder Tom Jadczyk Kasia Malaczynska-Rajpold Goanță Emilia Gonca Suna Martin Manninger Ivan Zeljkovic Henrike Hillmann Konstantinos Triantafyllou @MartinaNesti1 Marco Vitolo Ⓜ️ Francesco Santoro, MD, PhD Xiaodong Zhang (Andy), MD, PhD, FHRS, FACC Giulio Conte Dominik Linz

Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association (HFA) of the ESC onlinelibrary.wiley.com/doi/abs/10.100…

Remember your PV loops? New insights into #Takotsubo syndrome hemodynamics may cast light on new therapeutic targets! bit.ly/3MteFSN #JACC #CardioTwitter Thomas Stiermaier Ingo Eitel

Remote monitoring reduces #HeartFailure hospitalisations and improves quality of life 👇 #HeartFailure2023 #HF #HFA_ESC #MONIT0R_HF

Late breaking at #HeartFailure2023: In a phase 1 trial, NI006 had a favorable safety profile in patients with transthyretin amyloid cardiomyopathy. At doses of at least 10 mg per kilogram, amyloid-load surrogates appeared to be reduced. nej.md/42FG6P6

Implementation strategies that are proven-effective in trials are underutilized in clinical settings. Out now! Our latest paper published in JACC Journals #JACC Harriette Van Spall, MD MPH 🇨🇦 C. Michael Gibson MD @JJheart_doc Gregg Fonarow MD Prashanth Kulkarni MD, DM, FSCAI, FACC Tauben Averbuch MD sciencedirect.com/science/articl…

Some argued a sham-controlled trial would be impossible. Happy to announce that the team of Mathias Forkmann today randomized patient #100 into the PVI-sham-AF trial (NCT05119231). Great collaboration with @nikdagres Gerhard Hindricks Sergio Richter Thomas Gaspar BorislavDinov

📌#MIRACLE trial stopped early due to slow enrollment. 📌#Balcinrenone + #dapagliflozin showed non-significant #UACR reductions, no clear dose-response. 📌Hyperkalemia rare, but higher balcinrenone doses linked to increased serum potassium & ⬇️ #eGFR #HeartFailure2024

EASY-HF 📍Improved natriuresis & diuresis without increased adverse events in ADHF patients. 📍Bedside UNa sensor facilitates rapid diuretic adjustments by nurses, preferred over 24h UC. 📍Standardized protocol + UNa sensor allows personalized diuretic titration in first

Presented at #HeartFailure2024: Among patients with symptomatic obstructive hypertrophic cardiomyopathy, treatment with aficamten led to a greater increase in peak oxygen consumption than placebo at 6 months. Full SEQUOIA-HCM phase 3 trial results: nej.md/3wmDzyl

#HeartFailure2024 #JACC SimPub: In #ATTR-CA, the baseline 6MWT distance can refine risk stratification beyond traditional prognosticators. Worsening of 6MWT at 1 year was common and independently associated with an increased risk of mortality. bit.ly/44zzYtt #Amyloidosis

Study shows 6 months of treatment with sacubitril/valsartan in patients with #HeartFailure with reduced ejection fraction is associated with increased left ventricular contractility, reduced afterload, and improved ventricular-arterial coupling. ow.ly/rCQg50Ukp8E #HFrEF